Scrip: industry news and insights
GSK’s Dostarlimab Gets EU Nod For Endometrial Cancer
26 Feb 2021
While its NDA languishes at the US Food and Drug Administration, the EMA’s CHMP has said yes to dostarlimab’s marketing...
Executive Summary
Using Pharmapremia data, we analyze performance metrics for a select group of leading cancer companies to see where the sticking points are and who is winning at industry’s most important race.
As oncology drug development programs skyrocket and companies prioritize the therapeutic area, there’s a need to understand what is working and where the process needs to be improved.
Using performance metrics from Informa Pharma Intelligence’s Pharmapremia on transitions between clinical phases and the likelihood of approval from 2006-2010 and 2011-2015, it’s clear that as the number of cancer development programs has risen, success rates aren’t holding up.
“Despite the fact that more oncology candidates transitioned through and out of company pipelines over the last five years compared to the previous five, overall success rates took a dive industry-wide,” Informa Pharma Consulting’s Justin Burns said. “These data underscore just how dedicated the pharmaceutical industry has been, especially the major companies, to advancing the treatment paradigm for cancer.”
While performance was down strictly looking at success rates, Burns noted that for select companies that have concentrated on cancer, there has been an increase in overall approvals, from 39 to 52 for 2006-2010 and 2011-2015, respectively. “Despite the fact that the harder they tried, the more they failed, these companies continued to devote considerable R&D spend to their cancer pipelines,” he commented.
See below for more on which companies are standing above the pack and which areas have the best odds to make it to market.
Oncology Scorecard
Scrip: industry news and insights
26 Feb 2021
While its NDA languishes at the US Food and Drug Administration, the EMA’s CHMP has said yes to dostarlimab’s marketing...
Scrip: industry news and insights
By Anju Ghangurde 26 Feb 2021
Merck & Co. executive outlines how the company could sustain a “compliant supply performance” amid the pandemic, while senior officials...
Scrip: industry news and insights
By John Davis 26 Feb 2021
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies...
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: